Skip to main content

From Taylor Swift to the Oscars, 400-year-old ‘Hamlet’ flourishes in the age of TikTok

NEW YORK (AP) — He’s on screen, onstage, on tour, online and in song. “Hamlet” — William Shakespeare’s masterpiece about a moody Danish prince — seems to be having a moment.

A National Theatre production has landed at the Brooklyn Academy of Music starring Hiran Abeysekera. There’s a movie version set in London’s South Asian community starring Riz Ahmed. Anthony Hopkins, at 88, is delighting fans on TikTok with some of Prince Hamlet’s “To be, or not to be” soliloquy. The movie “Hamnet” — the fictionalized story of loss that inspired the creation of “Hamlet” — earned Jessie Buckley an Oscar. Taylor Swift’s “The Fate of Ophelia” — that’s Hamlet’s ex — went to No. 1 on the Billboard singles chart. Eddie Izzard is taking her one-person production of the play on a worldwide tour.

Four hundred years on, “Hamlet” — whose seemingly quite modern antihero is endlessly mulling over what to do after his uncle murdered his father and married his mother — is still giving.

Want even more? There’s even a “Hamnet” play, adapted from Maggie O’Farrell’s original novel, and the Royal Shakespeare Company is taking it on a U.K. tour. Shakespeare & Company will stage a “Hamlet” this August in the Berkshires. There’s a Canadian production of “Hamlet, Sweet Prince,” using a queer, contemporary lens. The Acting Company in New York will have a modern-verse version led by a woman, and the Peruvian theater company Teatro La Plaza recently presented a version off-Broadway starring eight Spanish-speaking actors with Down syndrome.

Harvard’s Jeffrey R. Wilson, a Shakespeare scholar, says “Hamlet” is perfect for our era, when the crush of bad news has triggered constant, existential check-ins, like: “Hey, how’s everyone hanging in there?”

“People are exhausted from the onslaught of awfulness in the world,” he says, “and ‘Hamlet’ gives audiences both permission to ‘go there’ to explore those emotions and a tool kit of ideas to help us process angst.”

A neurodiverse ‘Hamlet’

The plethora of works are markedly vibrant and fresh, from the Hamlet in Brooklyn who wears a beanie to the one who enjoys Bollywood-style dances in London.

“Great plays survive not because they remain untouched, but because they can continue to be transformed,” says director and playwright Chela De Ferrari, from Teatro La Plaza, whose neurodiverse “Hamlet” is a visceral and urgent call from those often excluded from cultural narratives.

“Working with actors with Down syndrome and cognitive disabilities brought me back to something essential in ‘Hamlet’: that beneath its philosophical brilliance there is an exposed human being asking, in one way or another, how to exist in a world that keeps misreading him,” she said.

In one of the show’s most potent moments, an actor attempts to imitate Laurence Olivier’s delivery of Hamlet’s “To be, or not to be” soliloquy with an image of the famous actor projected on a screen. It takes on a new urgency when spoken by someone whose very right to be in public or artistic spaces is often questioned.

“I like to imagine a kind of continuity between our actors and all the great actors who have carried the play before. I believe Shakespeare lives in all of them,” says De Ferrari.

Shakespeare in a BMW

On school trips to see Shakespeare plays, filmmaker Aneil Karia always felt like they were an arm’s length away.

“I felt like I was primarily watching an intellectual experience unfold and I had to use my brain to keep up with the plot and the language and everything like that,” he says.

He teamed up with Ahmed and screenwriter Michael Lesslie for a stripped-down, modern-day retelling of “Hamlet” that leans into the title character’s unease at being complicit in a corrupt business system.

“That feels so pertinent to the moment we’re in politically and everything. It feels like the question a lot of people are asking,” says Karia. “It feels like these stories are actually a conversation through time itself.”

Hamlet here parties at a neon-drenched nightclub and delivers his soliloquy while hurtling down rain-slicked London streets in a BMW, taking his hands off the wheel as a truck approaches head-on. To be, or not to be, indeed.

“The best best-case scenario here is that it’s opening up Shakespeare to audiences who didn’t think it was for them, or who struggled with it previously,” says Karia, whose film starts streaming Tuesday. “This is a big call, but I feel like Shakespeare would approve. I feel his whole thing was like, ‘Take this stuff and do your thing.’”

A more clownish prince

The “Hamlet” in Brooklyn leans into the humor of the play for one good reason: The guy playing Hamlet is naturally funny.

Abeysekera is manic and mischievous as he pulls out the play’s physical humor, addressing the audience directly in his soliloquies, sometimes sitting at the edge of the stage and making eye contact.

“It’s a very self-aware play. It sort of really knows that it’s a play, if that makes any kind of sense,” says director Robert Hastie. “Hamlet knows he’s in a play called ‘Hamlet,’ like Deadpool knows he is in a film called ‘Deadpool.’”

Abeysekera tackles his “To be, or not to be” speech as an errant thought, a wisp of an idea, instead of the traditional foot-planted, actor-y, big-thing-coming approach.

“Rather than thinking, ‘Oh, here’s the big speech coming up and that’s freaking me out,’ I started thinking, ‘It’s such a thought that most of us kind of have,’” he says. “Sometimes, in front of the mirror, we just see ourselves and go, ‘Oof. Today’s a tough day.’”

Hastie believes “Hamlet” is one of those works that reveals something new all the time. Grounded in the human condition, it speaks fresh things to each audience and we discover new things that have always been there.

“One of the reasons I think why we’re still talking about Shakespeare, and this play in particular, is that whenever those words fuse with a new actor or a new group of actors, it becomes a different play,” he says. “Maybe that’s a good working definition of a classic.”

An extremely online bard

Caitlin Cardile is doing her best to keep the 400-year-old playwright alive in the TikTok era. She and her three-person troupe Mad Spirits Theatre Company are on virtually every social media platform spreading the word.

“We wanted to bring Shakespeare to a modern audience and make it understandable,” Cardile says. “We want people to feel more comfortable with Shakespeare and not think that it’s old English and such a hard thing to understand.”

They post live readings and commentary of the plays on YouTube but it’s on Instagram and TikTok where the true coolness starts. They find trending audio snippets — of everything from dialogue on “The Office” to a Lady Gaga song — and assign a Shakespeare character to say them.

So Kitty Forman’s popular line “I may have been a little irrational today” from “That ’70s Show” is lipsynced by an actor playing Ophelia. A section of dialogue between Scar and Simba from “The Lion King” is put in the mouths of actors playing Claudius and Hamlet.

“We’re like, ‘Hey, wouldn’t it be funny if we took these silly trending sounds that everybody’s doing and what if we put them to Shakespeare characters?’” says Cardile. “This has ended up being so much fun.”

When you have advanced prostate cancer: What living with the disease looks like

(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story